Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition

Agcakaya, Esma; Mutlu, Hacer Hicran; Erbakan, Ayşe Naciye; Sargın, Mehmet

doi:10.29271/jcpsp.2023.03.308

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both SGLT2Is and metformin reduce the risk of macroangiopathy in patients with type 2 diabetes 13 , 14 , 15 , 16 , 17 , 18 , 19 . Herein, SGLT2Is reduced the risk of the composite end‐point compared with metformin, presumably because SGLT2Is improve hypertension 20 and obesity 21 , 22 , which are risk factors for NMI, AP and NS. Furthermore, on separate examination according to baseline characteristics, the risk reduction at the composite end‐point showed a similar trend, suggesting that patients with various conditions can benefit from SGLT2Is.…”

Section: Discussionmentioning

confidence: 99%

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan

Horii

Oikawa

Shimada

et al. 2023

J of Diabetes Invest

View full text Add to dashboard Cite

We aimed to compare the effects of cardiovascular disease risk in Japanese patients with type 2 diabetes on sodium–glucose cotransporter 2 inhibitors (SGLT2Is) or metformin. This retrospective, real‐world cohort study was carried out using a claims database and propensity score matching; 58,402 eligible patients (29,201 per group) were included. The outcomes included nonfatal myocardial infarction, angina pectoris, nonfatal stroke, hospitalization for heart failure and composite end‐points. The hazard ratio (HR) for the composite end‐point was 0.79, which was lower for SGLT2Is than for metformin. For male patients (HR 0.76), patients aged <65 years (HR 0.94), patients aged ≥75 years (HR 0.78) and patients with body mass index ≥25 kg/m2 (HR 0.76), the HRs for the composite end‐point were significantly lower in the SGLT2I group than in the metformin group. SGLT2Is might be superior to metformin in reducing the composite risk of cardiovascular disease in patients with type 2 diabetes.

show abstract